IPO Year: 2022
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann |
4/29/2024 | Buy → Neutral | Ladenburg Thalmann | |
3/1/2024 | $14.00 | Mkt Outperform | JMP Securities |
12/15/2023 | $17.00 → $12.00 | Buy | Jefferies |
10/5/2023 | Buy | Maxim Group | |
6/2/2023 | $25.00 | Outperform | Oppenheimer |
5/8/2023 | $25.00 | Outperform | BMO Capital Markets |
4/27/2023 | $22.00 | Buy | Ladenburg Thalmann |
4/20/2023 | $24.00 | Buy | H.C. Wainwright |
BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and maintains $25 price target.
HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and raises the price target from $20 to $22.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share from the same period last year.
Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.
BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target from $18 to $25.
JMP Securities analyst Silvan Tuerkcan maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and raises the price target from $14 to $17.
Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $26 to $30.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13D/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi
WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. "We are excited to welcome Ivana to our board of directors," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and fou
WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer. "Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon," said Peter Blume-Jense
WATERTOWN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs. "We are thrilled to have Adam join us as a proven leader in investor relations and corporate strategy," said Peter Blume-Jensen, M.D., Ph.D., chief ex
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that Charles (Chuck) Baum, M.D., Ph.D., founder, president, head of research and development, board member, and former chief executive officer of Mirati Therapeutics, has been appointed to Acrivon's board of directors. "We are thrilled about Chuck's appointment and look forward
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Ladenburg Thalmann downgraded Acrivon Therapeutics from Buy to Neutral
JMP Securities initiated coverage of Acrivon Therapeutics with a rating of Mkt Outperform and set a new price target of $14.00
Jefferies resumed coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $12.00 from $17.00 previously
Maxim Group initiated coverage of Acrivon Therapeutics with a rating of Buy
Oppenheimer initiated coverage of Acrivon Therapeutics with a rating of Outperform and set a new price target of $25.00
BMO Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Outperform and set a new price target of $25.00
Ladenburg Thalmann initiated coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $24.00
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
EFFECT - Acrivon Therapeutics, Inc. (0001781174) (Filer)
ARS - Acrivon Therapeutics, Inc. (0001781174) (Filer)
DEFA14A - Acrivon Therapeutics, Inc. (0001781174) (Filer)
DEF 14A - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type with potential for ACR-368 accelerated regulatory approval IND clearance and initial sites activated ahead of timelines for ACR-2316 with first-in-human dosing anticipated in Q4 2024 AP3
WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, September 17, 2024 at 8:35 a.m. ET at the Cantor Global Healthcare Conference in New York. To access the live webcast, visit the Events
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company will host a
WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Precision Predictive Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today reported financial results for the second quarter ended June 30, 2024 and reviewed business highlights. "We continue to make significant progress on our mission to deliver on the unique and actionable capabilities of our AP3 platform by rapidly advancing a pipeline of different
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, June 5, 2024 at 9:30 a.m. ET at the Jefferies Global Healthcare Conference in New York. To access
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the first quarter ended March 31, 2024 and reviewed business highlights. "Within the first few months of 2024, we have demonstrated significant progress across our AP3 platform and our clinical and preclinical pip
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers• Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038)• ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024• Acrivon hosts Corporate R&D event webcast today at 4:15 pm ET WATERTOWN, Mass., April 24, 2024 (GLO
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D event on April 24th, 2024 from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by Acrivon's leadership team followed by an interactive Q&A session. "We are very excited t
ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical studies and is planned for monotherapy clinical development AP3 profiling uncovered actionable pathways linked to resistance mechanisms for ACR-368, a clinical-stage CHK1/2 inhibitor, and identified ultra-low dose gemcitabine (ULDG) to sensitize resistant ovarian cancer cells to ACR-368 WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision onco
WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 8,235,000 shares of its common stock at a price of $8.50 per share, a premium to the closing